Activatory function appears to have a dominant role as judged from the studies of CD45-deficient mice and humans. CD148 Crizotinib supplier is another receptor-like protein tyrosine phosphatase (PTP),

which acts as a suppressor in solid tumors by inhibiting transduction of mitogenic signals. In hematopoietic cells, CD148 inhibits T-cell receptor signaling by dephosphorylating several key signaling molecules, including LAT and PLCγ. On the other hand, Tomáš Brdička’s data suggest that in B cells and macrophages CD148 augments immunoreceptor signaling via dephosphorylation of the C-terminal tyrosine of SFKs. Thus, it seems that CD148 may have the opposite function in T cells as compared with other leukocytes. To reconcile this controversy, Tomáš Brdička’s group analyzed the function of CD148 in human T-cell lines in a CD45-deficient setting. It was found that under these circumstances CD148 is able to dephosphorylate inhibitory tyrosines of SFKs and thus activate these kinases and rescue signaling defects caused by CD45 deficiency. The study suggests that dual inhibitory/stimulatory www.selleckchem.com/products/pexidartinib-plx3397.html function may be a common principle governing the signaling by different receptor-like PTPs. Gerhard Schütz (Linz, Austria) introduced the methodology behind the fascinating

world of single molecule microscopy. Current scientific research throughout the natural sciences aims at the exploration of structures with dimensions between 1 and 100 nm. In the life sciences, the diversity of this nanocosm attracts more and more researchers to the emerging field of nanobiotechnology. Gerhard Schütz explained how to obtain insights

Tyrosine-protein kinase BLK into the organization of the cellular compartments by single molecule experiments. He presented results on the interaction between antigen-loaded MHC and the T-cell receptor, looking directly at the interface region of a T cell with a mimic of an antigen-presenting cell. He also presented studies of the interaction between CD4 – the major coreceptor for T cell activation – and Lck, a tyrosine kinase important in early T cell signalling. Tumor immunology and cancer immunotherapy It was an honor to have the current EFIS President Catherine Sautès-Fridman (Paris, France) to start the session on tumor immunology. She illustrated the double role of the immune response in the outcome of cancer, presenting experimental data obtained from lung cancer patients 4. The density of mature DC, a cell population which homes exclusively to the T-cell areas of BALT, forming synapses with naive T cells, correlates with prolonged survival in patients with early-stage NSCLC. Catherine Sautès-Fridman hypothesized that tumor antigens that are continuously sampled and processed by DC activate T cells in situ, thereby increasing the efficiency of the immune response.